US panel supports multi-cancer blood test as Hong Kong doctors urge caution

A US Food and Drug Administration panel has voted in favour of recommending Grail’s Galleri blood test, marking a significant step for technology designed to detect several cancers through a single blood draw, the South China Morning Post reported. The test belongs to the emerging field of multi-cancer early detection, or MCED. These tests aim to identify signals associated with multiple cancers at once, rather than screening for only one disease through a dedicated examination.

The panel’s vote was described as the first time US regulators had endorsed the technology. The report did not say that the test had received final approval for routine use, nor did it provide details of the panel’s vote or the cancers the test is intended to detect. Doctors in Hong Kong remain cautious about wider adoption, according to the report.

They have raised questions about the test’s clinical value, suggesting that regulatory support in the United States does not by itself settle how useful the technology would be in everyday medical practice. The report said implementation in Hong Kong still faces challenges. The supplied material did not specify those challenges in detail, or explain how the test would be incorporated into existing screening programmes.

The development nevertheless gives momentum to efforts to use blood tests for multi-cancer detection. The debate now involves both the technology’s regulatory progress and the evidence needed for doctors to determine its practical role.